{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T16:42:11Z","timestamp":1784133731571,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,28]]},"DOI":"10.7759\/cureus.70411","type":"journal-article","created":{"date-parts":[[2024,9,29]],"date-time":"2024-09-29T06:42:05Z","timestamp":1727592125000},"source":"Crossref","is-referenced-by-count":2,"title":["The Efficacy and Safety of Inclisiran for Low-Density Lipoprotein (LDL) in Patients With Atherosclerotic Cardiovascular Disease (ASCVD): A Systematic Review of Randomized Controlled Trials"],"prefix":"10.7759","author":[{"given":"Hyder","family":"Mirghani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bandar H","family":"Albalawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed S","family":"Alshehri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waseem M","family":"Almalawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumaya","family":"Alanezi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Alarki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah A","family":"Alyahya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sultan","family":"Alshaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam S","family":"Shaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abeer","family":"AlAnazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1158274","article-title":"Efficacy and safety of inclisiran in stroke or cerebrovascular disease prevention: a systematic review and meta-analysis of randomized controlled trials","volume":"14","author":"Luo M","year":"2023","unstructured":"Luo M, Liu Y, Xu X, et al.. Efficacy and safety of inclisiran in stroke or cerebrovascular disease prevention: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2023, 14:1158274. 10.3389\/fphar.2023.1158274","journal-title":"Front Pharmacol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000147965.52712.fa","article-title":"Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis","volume":"35","author":"Amarenco P","year":"2004","unstructured":"Amarenco P, Labreuche J, Lavall\u00e9e P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke. 2004, 35:2902-9. 10.1161\/01.STR.0000147965.52712.fa","journal-title":"Stroke"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-021-01440-5","article-title":"Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review","volume":"21","author":"Bosco E","year":"2021","unstructured":"Bosco E, Hsueh L, McConeghy KW, Gravenstein S, Saade E. Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review. BMC Med Res Methodol. 2021, 21:241. 10.1186\/s12874-021-01440-5","journal-title":"BMC Med Res Methodol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000019377","article-title":"Carotid plaque magnetic resonance imaging and recurrent stroke risk: a systematic review and meta-analysis","volume":"99","author":"Deng F","year":"2020","unstructured":"Deng F, Mu C, Yang L, Li H, Xiang X, Li K, Yang Q. Carotid plaque magnetic resonance imaging and recurrent stroke risk: a systematic review and meta-analysis. Medicine (Baltimore). 2020, 99:e19377. 10.1097\/MD.0000000000019377","journal-title":"Medicine (Baltimore)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1080\/15476286.2022.2052641","article-title":"Advances in siRNA therapeutics and synergistic effect on siRNA activity using emerging dual ribose modifications","volume":"19","author":"Gangopadhyay S","year":"2022","unstructured":"Gangopadhyay S, Gore KR. Advances in siRNA therapeutics and synergistic effect on siRNA activity using emerging dual ribose modifications. RNA Biol. 2022, 19:452-67. 10.1080\/15476286.2022.2052641","journal-title":"RNA Biol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.12.006","article-title":"Lipids, lipoproteins, and metabolites and risk of myocardial infarction and stroke","volume":"71","author":"Holmes MV","year":"2018","unstructured":"Holmes MV, Millwood IY, Kartsonaki C, et al.. Lipids, lipoproteins, and metabolites and risk of myocardial infarction and stroke. J Am Coll Cardiol. 2018, 71:620-32. 10.1016\/j.jacc.2017.12.006","journal-title":"J Am Coll Cardiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani M","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016, 5:210. 10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604.ch8","article-title":"Assessing risk of bias in a randomized trial","author":"Higgins JP","year":"2019","unstructured":"Higgins JP, Savovi\u0107 J, Page MJ, Elbers RG, Sterne JC. Assessing risk of bias in a randomized trial. Cochrane Handbook for Systematic Reviews of Interventions. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (ed): Wiley, Hoboken, NJ; 2019. 5:205-28. 10.1002\/9781119536604.ch8"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.03.382","article-title":"An \u201cinclisiran first\u201d strategy vs usual care in patients with atherosclerotic cardiovascular disease","volume":"83","author":"Koren MJ","year":"2024","unstructured":"Koren MJ, Rodriguez F, East C, et al.. An \u201cinclisiran first\u201d strategy vs usual care in patients with atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2024, 83:1939-52. 10.1016\/j.jacc.2024.03.382","journal-title":"J Am Coll Cardiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacasi.2023.09.006","article-title":"Efficacy and safety of inclisiran in Asian patients: results from ORION-18","volume":"4","author":"Huo Y","year":"2024","unstructured":"Huo Y, Lesogor A, Lee CW, et al.. Efficacy and safety of inclisiran in Asian patients: results from ORION-18. JACC Asia. 2024, 4:123-34. 10.1016\/j.jacasi.2023.09.006","journal-title":"JACC Asia"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.12.058","article-title":"Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis","volume":"77","author":"Wright RS","year":"2021","unstructured":"Wright RS, Ray KK, Raal FJ, et al.. Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis. J Am Coll Cardiol. 2021, 77:1182-93. 10.1016\/j.jacc.2020.12.058","journal-title":"J Am Coll Cardiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(22)00353-9","article-title":"Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial","volume":"11","author":"Ray KK","year":"2023","unstructured":"Ray KK, Troquay RP, Visseren FL, et al.. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. Lancet Diabetes Endocrinol. 2023, 11:109-19. 10.1016\/S2213-8587(22)00353-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2022-002184","article-title":"Lipid lowering with inclisiran: a real-world single-centre experience","volume":"9","author":"Padam P","year":"2022","unstructured":"Padam P, Barton L, Wilson S, et al.. Lipid lowering with inclisiran: a real-world single-centre experience. Open Heart. 2022, 9:26-8. 10.1136\/openhrt-2022-002184","journal-title":"Open Heart"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray KK","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, et al.. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020, 382:1507-19. 10.1056\/NEJMoa1912387","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"crossref","DOI":"10.7196\/SAMJ.2022.v112i6.16253","article-title":"Safety and efficacy of inclisiran in South African patients at high cardiovascular risk: a subanalysis of the ORION phase III clinical trials","volume":"112","author":"Raal F","year":"2022","unstructured":"Raal F, Abelson M, Blignaut S, et al.. Safety and efficacy of inclisiran in South African patients at high cardiovascular risk: a subanalysis of the ORION phase III clinical trials. S Afr Med J. 2022, 112:426-32.","journal-title":"S Afr Med J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/HCO.0000000000001074","article-title":"Inclisiran and cardiovascular events: a comprehensive review of efficacy, safety, and future perspectives","volume":"38","author":"Mohamed AA","year":"2023","unstructured":"Mohamed AA, Ray KK. Inclisiran and cardiovascular events: a comprehensive review of efficacy, safety, and future perspectives. Curr Opin Cardiol. 2023, 38:527-32. 10.1097\/HCO.0000000000001074","journal-title":"Curr Opin Cardiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2293201","article-title":"A systematic review and meta-analysis of tolerability, cardiac safety and efficacy of inclisiran for the therapy of hyperlipidemic patients","volume":"23","author":"Dutta S","year":"2024","unstructured":"Dutta S, Shah R, Singhal S, Singh S, Piparva K, Katoch CD. A systematic review and meta-analysis of tolerability, cardiac safety and efficacy of inclisiran for the therapy of hyperlipidemic patients. Expert Opin Drug Saf. 2024, 23:187-98. 10.1080\/14740338.2023.2293201","journal-title":"Expert Opin Drug Saf"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2023.06.011","article-title":"Inclisiran for the treatment of hyperlipidemia and for atherosclerotic cardiovascular disease risk reduction: a narrative review","volume":"45","author":"Cowart K","year":"2023","unstructured":"Cowart K, Singleton J, Carris NW. Inclisiran for the treatment of hyperlipidemia and for atherosclerotic cardiovascular disease risk reduction: a narrative review. Clin Ther. 2023, 45:1099-104. 10.1016\/j.clinthera.2023.06.011","journal-title":"Clin Ther"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2635","article-title":"Meta-analysis of clinical outcomes of PCSK9 modulators in patients with established ASCVD","volume":"41","author":"Talasaz AH","year":"2021","unstructured":"Talasaz AH, Ho AJ, Bhatty F, Koenig RA, Dixon DL, Baker WL, Van Tassell BW. Meta-analysis of clinical outcomes of PCSK9 modulators in patients with established ASCVD. Pharmacotherapy. 2021, 41:1009-23. 10.1002\/phar.2635","journal-title":"Pharmacotherapy"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjco.2022.03.003","article-title":"Real-world insights into Evolocumab use in patients with hyperlipidemia: Canadian analysis from the ZERBINI Study","volume":"4","author":"Gupta M","year":"2022","unstructured":"Gupta M, Mancini GB, Wani RJ, et al.. Real-world insights into Evolocumab use in patients with hyperlipidemia: Canadian analysis from the ZERBINI Study. CJC Open. 2022, 4:558-67. 10.1016\/j.cjco.2022.03.003","journal-title":"CJC Open"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/metabo12030256","article-title":"Insight into the evolving role of PCSK9","volume":"12","author":"Malig\u0142\u00f3wka M","year":"2022","unstructured":"Malig\u0142\u00f3wka M, Kosowski M, Hachu\u0142a M, et al.. Insight into the evolving role of PCSK9. Metabolites. 2022, 12:14-6. 10.3390\/metabo12030256","journal-title":"Metabolites"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01287-6","article-title":"Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: an analysis from BANTING and BERSON","volume":"20","author":"Lorenzatti AJ","year":"2021","unstructured":"Lorenzatti AJ, Monsalvo ML, L\u00f3pez JA, Wang H, Rosenson RS. Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: an analysis from BANTING and BERSON. Cardiovasc Diabetol. 2021, 20:94. 10.1186\/s12933-021-01287-6","journal-title":"Cardiovasc Diabetol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01283-w","article-title":"Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus","volume":"20","author":"Fischer LT","year":"2021","unstructured":"Fischer LT, Hochfellner DA, Knoll L, P\u00f6ttler T, Mader JK, Aberer F. Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus. Cardiovasc Diabetol. 2021, 20:89. 10.1186\/s12933-021-01283-w","journal-title":"Cardiovasc Diabetol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"73","author":"Grundy SM","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al.. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol. 2019, 73:e285-350. 10.1016\/j.jacc.2018.11.003","journal-title":"J Am Coll Cardiol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2019.12.004","article-title":"Corrigendum to \"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk\" [Atherosclerosis 290 (2019) 140-205]","volume":"294","year":"2020","unstructured":"Corrigendum to \"2019 ESC\/EAS Guidelines for the management of dyslipidaemias. lipid modification to reduce cardiovascular risk\" [Atherosclerosis 290 (2019) 140-205]. Atherosclerosis. 2020, 294:80-2. 10.1016\/j.atherosclerosis.2019.12.004","journal-title":"Atherosclerosis"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.495","article-title":"The implications of therapeutic complexity on adherence to cardiovascular medications","volume":"171","author":"Choudhry NK","year":"2011","unstructured":"Choudhry NK, Fischer MA, Avorn J, et al.. The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med. 2011, 171:814-22. 10.1001\/archinternmed.2010.495","journal-title":"Arch Intern Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31950-6","article-title":"Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options","volume":"394","author":"Ray KK","year":"2019","unstructured":"Ray KK, Corral P, Morales E, Nicholls SJ. Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options. Lancet. 2019, 394:697-708. 10.1016\/S0140-6736(19)31950-6","journal-title":"Lancet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/290320-the-efficacy-and-safety-of-inclisiran-for-low-density-lipoprotein-ldl-in-patients-with-atherosclerotic-cardiovascular-disease-ascvd-a-systematic-review-of-randomized-controlled-trials","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,29]],"date-time":"2024-09-29T06:42:08Z","timestamp":1727592128000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/290320-the-efficacy-and-safety-of-inclisiran-for-low-density-lipoprotein-ldl-in-patients-with-atherosclerotic-cardiovascular-disease-ascvd-a-systematic-review-of-randomized-controlled-trials"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,28]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.70411","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,28]]}}}